HI SB1042

Establishes a two-year Mental Health Emerging Therapies Pilot Program within the Office of Wellness and Resilience to support clinical research on psychedelic and entactogenic compounds for treating mental health disorders

Focuses on addressing veteran mental health needs, particularly high rates of suicide and PTSD, through FDA breakthrough-designated therapies like MDMA-assisted therapy and psilocybin treatment

Authorizes the pilot program to fund phase three clinical trials, education and training for mental health professionals, public education, harm reduction efforts, and implementation studies

Requires the Office of Wellness and Resilience to submit annual reports to the legislature before the 2026 and 2027 sessions detailing funded studies, findings, recommendations, and proposed legislation

Appropriates an unspecified amount from general revenues for fiscal years 2025-2026 and 2026-2027, with the program set to expire on June 30, 2027